+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Cancer Immunotherapy Market - Premium Insight, Industry Trends, FPNV Positioning Matrix, Competitive News Feed Analysis, Company Usability Profiles, Market Sizing & Forecasts to 2024 (Q1 2019 Update)

  • ID: 4761621
  • Report
  • Region: Global
  • 159 pages
  • 360iResearch
1 of 5

FEATURED COMPANIES

  • Amgen Inc.
  • Bayer AG
  • Celgene Corporation
  • F. Hoffmann-La Roche Ltd
  • Merck
  • Pfizer
  • MORE
The global cancer immunotherapy market is expected to grow from USD 76,523.68 million 2017 to USD 220,315.85 million by the end of 2024 at a Compound Annual Growth Rate (CAGR) of 16.31%.

“Growing incidences of cancer is one of the factors largely attributing to the growth of cancer immunotherapy market globally”

The factors attributing to the growth of the market are growing incidences of cancer, adoption of immunotherapy over other treatment options, development of bioinformatic tools enhancing the drug development process, rise in healthcare expenditure and healthcare insurance, and technological advancement and r&d for the treatment of cancer. However, some factors such as and high cost associated with the treatment may hinder the market growth. The global cancer immunotherapy market is expected to showcase the opportunities such as clinical trials to cure different cancers in immunotherapy, moving toward personalized immunotherapy, and combination of modern immunotherapy and traditional medicines increasing survival rate. In the near future, the market may face the possible challenges in the growth due to and cancer limiting the immune response. However, the key players in the market are putting regressive efforts to provide innovative offerings and benchmark strategies in the global cancer immunotherapy market.

“Breast Cancer: The highest growing function for the global cancer immunotherapy market”

On the basis of function, the global cancer immunotherapy market is studied across Breast Cancer, Colorectal Cancer, Head & Neck Cancer, Lung Cancer, Melanoma, Multiple Myeloma, and Prostate Cancer. Among all these function, the Breast Cancer is projected to hold the largest market share while the Lung Cancer has the potential to grow the market with the highest CAGR in the forecast period.

“Monoclonal Antibodies: The highest growing product for the global cancer immunotherapy market”

On the basis of product, the global cancer immunotherapy market is studied across Cell Therapies, Checkpoint Inhibitors, Immunomodulators, Monoclonal Antibodies, and Vaccines. Among all these product, the Monoclonal Antibodies is projected to hold the largest market share while the Checkpoint Inhibitors has the potential to grow the market with the highest CAGR in the forecast period.

“Hospitals: The highest growing end user for the global cancer immunotherapy market”

On the basis of end user, the global cancer immunotherapy market is studied across Cancer Research Institutes, Clinics, and Hospitals. Among all these end user, the Hospitals has captured the maximum market share while the Cancer Research Institutes has the opportunity to emerge with the highest CAGR.

“Americas: The highest growing geography for the global cancer immunotherapy market”

On the basis of geography, the global cancer immunotherapy market is studied across Americas, (United States, Brazil, Canada, Mexico, and Argentina) Europe, Middle East & Africa, (United Kingdom, Germany, France, Saudi Arabia, United Arab Emirates, Italy, and Russia) and Asia-Pacific (China, Japan, India, and Australia). Among all these geography, the Europe, Middle East & Africa is showing the maximum growth in the near future with the highest CAGR while the Americas is dominating the market with highest market size.

“Amgen Inc.: The potential growing player for the global cancer immunotherapy market”

The key players profiled in the global cancer immunotherapy market are Amgen Inc., Astrazeneca, Bayer AG, Bristol-Myers Squibb, Celgene Corporation, ELI Lilly and Company, F. Hoffmann-La Roche Ltd, GlaxoSmithKline Plc, Janssen Global Services, LLC, Merck, Novartis, Pfizer, Seattle Genetics, Inc., and Spectrum Pharmaceuticals, Inc..

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on sulfuric acid offered by the key players in the global cancer immunotherapy market.
2. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developments in the global cancer immunotherapy market.
3. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets for the global cancer immunotherapy market.
4. Market Diversification: Provides detailed information about new products launches, untapped geographies, recent developments, and investments in the global cancer immunotherapy market.
5. Competitive Assessment & Intelligence: Provides exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players in the global cancer immunotherapy market.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Amgen Inc.
  • Bayer AG
  • Celgene Corporation
  • F. Hoffmann-La Roche Ltd
  • Merck
  • Pfizer
  • MORE
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Stakeholders

2. Research & Forecasting
2.1. Research Methodology
2.1.1. Research Instruments
2.1.1.1. Secondary Instrument
2.1.1.2. Primary Instrument
2.1.2. Research Approaches
2.1.2.1. Bottom-up Approach
2.1.2.2. Top-down Approach
2.1.3. Research Reliability & Validity
2.1.4. Research Assumptions
2.1.5. Vendor Inclusion Criteria
2.2. Forecasting Methodology
2.2.1. Methodology for Market Estimation & Forecasting
2.2.2. Significance and Importance of the Market Estimation & Forecasting

3. Executive Summary

4. Premium Insight
4.1. Market Connectivity
4.2. Market Dynamics
4.2.1. Drivers
4.2.1.1. Growing incidences of cancer
4.2.1.2. Adoption of immunotherapy over other treatment options
4.2.1.3. Development of bioinformatic tools enhancing the drug development process
4.2.1.4. Rise in healthcare expenditure and healthcare insurance
4.2.1.5. Technological advancement and R&D for the treatment of cancer
4.2.2. Restraints
4.2.2.1. High cost associated with the treatment
4.2.3. Opportunities
4.2.3.1. Clinical trials to cure different cancers in immunotherapy
4.2.3.2. Moving toward personalized immunotherapy
4.2.3.3. Combination of modern immunotherapy and traditional medicines increasing survival rate
4.2.4. Challenges
4.2.4.1. Cancer limiting the immune response
4.3. Porter’s Five Forces Analysis
4.3.1. Threat of New Entrants
4.3.2. Threat of Substitutes
4.3.3. Bargaining Power of Customers
4.3.4. Bargaining Power of Suppliers
4.3.5. Industry Rivalry

5. Market Data Feed
5.1. Introduction
5.2. Global Cancer Immunotherapy Market, by Function
5.2.1. Breast Cancer
5.2.2. Colorectal Cancer
5.2.3. Head & Neck Cancer
5.2.4. Lung Cancer
5.2.5. Melanoma
5.2.6. Multiple Myeloma
5.2.7. Prostate Cancer
5.3. Global Cancer Immunotherapy Market, by Product
5.3.1. Cell Therapies
5.3.1.1. Chimeric Antigen Receptor T Cell Therapy
5.3.1.2. Dendritic Cells
5.3.2. Checkpoint Inhibitors
5.3.2.1. Cytotoxic T-Lymphocyte-Associated Protein-4
5.3.2.2. Programmed Death 1 & Programmed Death Ligand 1
5.3.3. Immunomodulators
5.3.3.1. Granulocyte-Macrophage Colony-Stimulating Factor
5.3.3.2. Interferons
5.3.3.3. Interleukins
5.3.3.4. Oncolytic Virus
5.3.4. Monoclonal Antibodies
5.3.4.1. Bispecific Monoclonal Antibodies
5.3.4.2. Conjugated Monoclonal Antibodies
5.3.4.3. Naked Monoclonal Antibodies
5.3.5. Vaccines
5.3.5.1. Prophylactic Vaccines
5.3.5.2. Therapeutic Vaccines
5.4. Global Cancer Immunotherapy Market, by End User
5.4.1. Cancer Research Institutes
5.4.2. Clinics
5.4.3. Hospitals
5.5. Global Cancer Immunotherapy Market, by Geography

6. Americas Cancer Immunotherapy Market
6.1. Americas Cancer Immunotherapy Market, by Country
6.1.1. United States
6.1.2. Brazil
6.1.3. Canada
6.1.4. Mexico
6.1.5. Argentina
6.2. Americas Cancer Immunotherapy Market, by Function
6.3. Americas Cancer Immunotherapy Market, by Product
6.4. Americas Cancer Immunotherapy Market, by End User

7. Europe, Middle East & Africa Cancer Immunotherapy Market
7.1. Europe, Middle East & Africa Cancer Immunotherapy Market, by Country
7.1.1. United Kingdom
7.1.2. Germany
7.1.3. France
7.1.4. Saudi Arabia
7.1.5. United Arab Emirates
7.1.6. Italy
7.1.7. Russia
7.2. Europe, Middle East & Africa Cancer Immunotherapy Market, by Function
7.3. Europe, Middle East & Africa Cancer Immunotherapy Market, by Product
7.4. Europe, Middle East & Africa Cancer Immunotherapy Market, by End User

8. Asia-Pacific Cancer Immunotherapy Market
8.1. Asia-Pacific Cancer Immunotherapy Market, by Country
8.1.1. China
8.1.2. Japan
8.1.3. India
8.1.4. Australia
8.2. Asia-Pacific Cancer Immunotherapy Market, by Function
8.3. Asia-Pacific Cancer Immunotherapy Market, by Product
8.4. Asia-Pacific Cancer Immunotherapy Market, by End User

9. Competitive Strategic Window
9.1. Introduction
9.1.1. Leverage Zone
9.1.2. Vantage Zone
9.1.3. Speculative Zone
9.1.4. Bottleneck Zone

10. Competitive Landscape
10.1. FPNV Positioning Matrix
10.1.1. Introduction
10.1.2. Scores
10.1.2.1. Forefront
10.1.2.2. Pathfinders
10.1.2.3. Niche
10.1.2.4. Vital
10.1.3. Business Strategy
10.1.4. Product Satisfaction
10.2. Market Vendor Ranking Analysis
10.3. Competitive News Feed Analysis

11. Company Usability Profiles
11.1. Amgen Inc.
11.2. Astrazeneca
11.3. Bayer AG
11.4. Bristol-Myers Squibb
11.5. Celgene Corporation
11.6. ELI Lilly and Company
11.7. F. Hoffmann-La Roche Ltd
11.8. GlaxoSmithKline Plc
11.9. Janssen Global Services, LLC
11.10. Merck
11.11. Novartis
11.12. Pfizer
11.13. Seattle Genetics, Inc.
11.14. Spectrum Pharmaceuticals, Inc.

12. Appendix
12.1. Top Reports
12.2. Author Details

LIST OF TABLES
TABLE 1. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, 2016 - 2024 (USD MILLION)
TABLE 2. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2016 - 2024 (USD MILLION)
TABLE 3. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2016 - 2024 (USD MILLION)
TABLE 4. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2016 - 2024 (USD MILLION)
TABLE 5. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY GEOGRAPHY, 2016 - 2024 (USD MILLION)
TABLE 6. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2016 - 2024 (USD MILLION)
TABLE 7. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2016 - 2024 (USD MILLION)
TABLE 8. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2016 - 2024 (USD MILLION)
TABLE 9. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2016 - 2024 (USD MILLION)
TABLE 10. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2016 - 2024 (USD MILLION)
TABLE 11. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2016 - 2024 (USD MILLION)
TABLE 12. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2016 - 2024 (USD MILLION)
TABLE 13. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2016 - 2024 (USD MILLION)
TABLE 14. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2016 - 2024 (USD MILLION)
TABLE 15. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2016 - 2024 (USD MILLION)
TABLE 16. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2016 - 2024 (USD MILLION)
TABLE 17. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2016 - 2024 (USD MILLION)
TABLE 18. Scores FOR FOREFRONT IN CANCER IMMUNOTHERAPY MARKET
TABLE 19. Scores FOR PATHFINDERS IN CANCER IMMUNOTHERAPY MARKET
TABLE 20. Scores FOR NICHE IN CANCER IMMUNOTHERAPY MARKET
TABLE 21. Scores FOR VITAL IN CANCER IMMUNOTHERAPY MARKET
TABLE 22. FPNV POSITIONING MATRIX BUSINESS STRATEGY FOR CANCER IMMUNOTHERAPY MARKET
TABLE 23. FPNV POSITIONING MATRIX PRODUCT SATISFACTION FOR CANCER IMMUNOTHERAPY MARKET
TABLE 24. GLOBAL CANCER IMMUNOTHERAPY MARKET RANKING, BY VENDORS, 2017

LIST OF FIGURES
FIGURE 1. GLOBAL CANCER IMMUNOTHERAPY MARKET: YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL CANCER IMMUNOTHERAPY MARKET: KEY RESEARCH METHODOLOGY
FIGURE 3. GLOBAL CANCER IMMUNOTHERAPY MARKET: KEY RESEARCH INSTRUMENTS
FIGURE 4. GLOBAL CANCER IMMUNOTHERAPY MARKET: KEY SECONDARY INSTRUMENT SOURCES
FIGURE 5. GLOBAL CANCER IMMUNOTHERAPY MARKET: KEY POTENTIAL RESPONDENTS
FIGURE 6. GLOBAL CANCER IMMUNOTHERAPY MARKET: KEY BREAKDOWN OF PRIMARY INSTRUMENT
FIGURE 7. GLOBAL CANCER IMMUNOTHERAPY MARKET: KEY RESEARCH APPROACHES
FIGURE 8. GLOBAL CANCER IMMUNOTHERAPY MARKET: KEY DATA TRIANGULATION
FIGURE 9. GLOBAL CANCER IMMUNOTHERAPY MARKET: KEY RESEARCH ASSUMPTIONS
FIGURE 10. CANCER IMMUNOTHERAPY MARKET: KEY MARKET CONNECTIVITY
FIGURE 11. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, 2016 - 2024 (USD MILLION)
FIGURE 12. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2017 VS 2024 (USD MILLION)
FIGURE 13. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2017 VS 2024 (USD MILLION)
FIGURE 14. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2017 VS 2024 (USD MILLION)
FIGURE 15. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY GEOGRAPHY, 2017 (USD MILLION)
FIGURE 16. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2017 VS 2024 (USD MILLION)
FIGURE 17. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2017 VS 2024 (USD MILLION)
FIGURE 18. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2017 VS 2024 (USD MILLION)
FIGURE 19. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2017 VS 2024 (USD MILLION)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2017 VS 2024 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2017 VS 2024 (USD MILLION)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2017 VS 2024 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2017 VS 2024 (USD MILLION)
FIGURE 24. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2017 VS 2024 (USD MILLION)
FIGURE 25. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2017 VS 2024 (USD MILLION)
FIGURE 26. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2017 VS 2024 (USD MILLION)
FIGURE 27. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2017 VS 2024 (USD MILLION)
FIGURE 28. Competitive Strategic Window FOR GLOBAL CANCER IMMUNOTHERAPY MARKET, BY FUNCTION, 2024
FIGURE 29. Competitive Strategic Window FOR GLOBAL CANCER IMMUNOTHERAPY MARKET, BY PRODUCT, 2024
FIGURE 30. Competitive Strategic Window FOR GLOBAL CANCER IMMUNOTHERAPY MARKET, BY END USER, 2024
FIGURE 31. Competitive Strategic Window FOR GLOBAL CANCER IMMUNOTHERAPY MARKET, BY GEOGRAPHY, 2024
FIGURE 32. FPNV POSITIONING MATRIX FOR CANCER IMMUNOTHERAPY MARKET
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Amgen Inc.
  • Bayer AG
  • Celgene Corporation
  • F. Hoffmann-La Roche Ltd
  • Merck
  • Pfizer
  • MORE
The global cancer immunotherapy market is expected to grow at a Compound Annual Growth Rate (CAGR) of 16.31% from 2017 to 2024 to reach USD 220,315.85 million.

In the report, we have covered two proprietary models, the FPNV Positioning Matrix and Competitive Strategic Window. The FPNV Positioning Matrix analyses the competitive market place for the players in terms of product satisfaction and business strategy they adopt to sustain in the market. The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisitions strategies, geography expansion, research & development, new product introduction strategies to execute further business expansion and growth.

Research Methodology:

Our market forecasting is based on a market model derived from market connectivity, dynamics, and identified influential factors around which assumptions about the market are made. These assumptions are enlightened by fact-bases, put by primary and secondary research instruments, regressive analysis and an extensive connect with industry people. Market forecasting derived from in-depth understanding attained from future market spending patterns provides quantified insight to support your decision-making process. The interview is recorded, and the information gathered in put on the drawing board with the information collected through secondary research.

The key chapters profiled in the report are as follows:1. Preface2. Research & Forecasting3. Executive Summary4. Premium Insight5. Market Data Feed6. Americas Cancer Immunotherapy Market7. Europe, Middle East & Africa Cancer Immunotherapy Market8. Asia-Pacific Cancer Immunotherapy Market9. Competitive Strategic Window10. Competitive Landscape11. Company Usability Profiles12. Appendix

The report answers questions such as:

1. What is the market size of cancer immunotherapy market in the global?
2. What are the factors that affect the growth in global cancer immunotherapy market over the forecast period?
3. What is the competitive position in the global cancer immunotherapy market?
4. Which are the best product areas to be invested in over the forecast period?
5. What are the opportunities in the global cancer immunotherapy market?
6. What are the modes of entering the global cancer immunotherapy market?
Note: Product cover images may vary from those shown
5 of 5
  • Amgen Inc.
  • Astrazeneca
  • Bayer AG
  • Bristol-Myers Squibb
  • Celgene Corporation
  • ELI Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline Plc
  • Janssen Global Services, LLC
  • Merck
  • Novartis
  • Pfizer
  • Seattle Genetics, Inc.
  • Spectrum Pharmaceuticals, Inc.
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/4761621
Adroll
adroll